H. Rept. 116-695: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019, Report to Accompany H.R. 5133, December 24, 2020 [open pdf - 306KB]
From the Purpose and Summary: "H.R. 5133, the 'Affordable Prescriptions for Patients Through Promoting Competition Act,' prohibits 'product hopping,' a particularly abusive form of anti-competitive conduct used by drug manufacturers to protect and extend their monopolies on prescription drugs. Product hopping occurs when a branded drug manufacturer seeks to extend its market exclusivity on a drug for which its patent is about to expire by switching doctors and patients from the old version to a new version, which may not offer any improvements in effectiveness or safety. This practice allows a pharmaceutical company to continue to reap monopoly profits by preventing generic substitution for its new, but not necessarily improved, version of the drug. The result can be years of additional market exclusivity for the pharmaceutical company without substantial improvements for patients in terms of effectiveness or safety."
H. Rept. 116-695; House Report 116-695
U.S. Government Publishing Office: http://www.gpo.gov/